ultragenyx.comRare Genetic Diseases | Ultragenyx
ultragenyx.com Profile
ultragenyx.com
Sub Domains:ir.ultragenyx.com
Title:Rare Genetic Diseases | Ultragenyx
Description:Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
Discover ultragenyx.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ultragenyx.com Information
Website / Domain: |
ultragenyx.com |
HomePage size: | 35.83 KB |
Page Load Time: | 0.898709 Seconds |
Website IP Address: |
69.63.140.80 |
Isp Server: |
Edgewebhosting.net |
ultragenyx.com Ip Information
Ip Country: |
United States |
City Name: |
Baltimore |
Latitude: |
39.294605255127 |
Longitude: |
-76.623489379883 |
ultragenyx.com Keywords accounting
ultragenyx.com Httpheader
Date: Sun, 18 Oct 2020 12:10:17 GMT |
Server: Apache |
X-Frame-Options: SAMEORIGIN |
Vary: User-Agent,Accept-Encoding |
ETag: 3gvogr |
Cache-Control: max-age=30, s-maxage=30 |
Expires: Sun, 18 Oct 2020 12:12:17 GMT |
Content-Encoding: gzip |
Content-Length: 3752 |
Keep-Alive: timeout=5, max=100 |
Connection: Keep-Alive |
Content-Type: text/html;charset=UTF-8 |
ultragenyx.com Meta Info
content="text/html; charset=utf-8" http-equiv="Content-Type"/ |
content="Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies." name="description"/ |
content="width=device-width, initial-scale=1.0" name="viewport"/ |
content="IE=edge" http-equiv="X-UA-Compatible"/ |
69.63.140.80 Domains
ultragenyx.com Similar Website
Domain |
WebSite Title |
ultragenyx.com | Rare Genetic Diseases | Ultragenyx |
geneticgladiator.weebly.com | Genetic Gladiator - Mutants:Genetic Gladiators Walkthrough |
rarepenny.nashvillecoin.com | Nashville Coin & Currency Rare Penny, Rare Coins |
cgsc2.biology.yale.edu | Coli Genetic Stock Center - E coli Genetic Resources at Yale |
story.rare-cancer.org | Rare Cancer : Rare Cancer Stories |
alliedgeneticresources.dvauction.com | Allied Genetic Resources |
geneticalgorithms.ai-depot.com | Genetic Algorithms Warehouse |
progenygenetics.com | Genetic Pedigree Software - Progeny |
cfgd.cochrane.org | Welcome | Cochrane Cystic Fibrosis and Genetic Disorders |
absglobal.com | ABS Global – Profit From Genetic Progress |
23andme.com | DNA Genetic Testing & Analysis - 23andMe |
natera.com | Natera | Transforming Management of Genetic Disease. |
agtc.com | News Applied Genetic Technologies Corporation |
geneticexcellence.dvauction.com | Genetic Excellence Angus Bull Sale |
abs-bs.absglobal.com | ABS Global – Profit From Genetic Progress |
ultragenyx.com Traffic Sources Chart
ultragenyx.com Alexa Rank History Chart
ultragenyx.com Html To Plain Text
As the COVID-19 pandemic continues to evolve, we are committed to the health and safety of our community including patients, caregivers, healthcare providers, partners, and employees. For patients specifically, this means that we are committed to our goal of continuing to deliver an uninterrupted supply of our medicines to the patients who rely on them. For more information, visit our COVID-19 Information page Transforming good science into great medicine for rare genetic diseases. Deep and diversified product pipeline Developing multiple clinical-stage programs in parallel Focused on serious rare and ultra-rare diseases Working with patients and medical professionals to treat rare diseases Dedicated to creating new treatments Join a high-performance team focused on rare diseases Full prescribing Information > See press release > September 25, 2020 Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit September 3, 2020 Ultragenyx to Present at Upcoming Investor Conferences September 2, 2020 Ultragenyx Appoints Mardi C. Dier as Chief Financial Officer About Management Emil D. Kakkis, M.D., Ph.D. Camille Bedrosian, M.D. Mardi Dier Erik Harris Dennis Huang Thomas Kassberg Ernie Meyer Karah Parschauer John Pinion Shalini Sharp Board of Directors Daniel G. Welch Emil D. Kakkis, M.D., Ph.D. William Aliski Deborah Dunsire, M.D. Lars Ekman, M.D., Ph.D. Matthew K. Fust Michael Narachi Clay B. Siegall, Ph.D. Shehnaaz Suliman, M.D. Grants & Charitable Contributions Message from BIO Medicines Crysvita® Mepsevii® Dojolvi™ Pipeline DTX 301 for OTC DTX 401 for GSDIa Presentations & Publications For Patients XLH TIO MPS 7 LC-FAOD OTC GSD1a Access to Approved Therapies Access to Investigational Therapies Investors Press Releases Events & Presentations Corporate Governance Management Board of Directors Committee Composition SEC Filings Stock Information Analyst Coverage Investor FAQ Contact Us Careers Culture Benefits Talent Network Jobs Partnering Current Partnerships Contact Driving Directions Home About Management Emil D. Kakkis, M.D., Ph.D. Camille Bedrosian, M.D. Mardi Dier Erik Harris Dennis Huang Thomas Kassberg Ernie Meyer Karah Parschauer John Pinion Shalini Sharp Board of Directors Daniel G. Welch Emil D. Kakkis, M.D., Ph.D. William Aliski Deborah Dunsire, M.D. Lars Ekman, M.D., Ph.D. Matthew K. Fust Michael Narachi Clay B. Siegall, Ph.D. Shehnaaz Suliman, M.D. Grants & Charitable Contributions Message from BIO Medicines Crysvita® Mepsevii® Dojolvi™ Pipeline DTX 301 for OTC DTX 401 for GSDIa Presentations & Publications For Patients XLH TIO MPS 7 LC-FAOD OTC GSD1a Access to Approved Therapies Access to Investigational Therapies Investors Press Releases Events & Presentations Corporate Governance Management Board of Directors Committee Composition SEC Filings Stock Information Analyst Coverage Investor FAQ Contact Us Careers Culture Benefits Talent Network Jobs Partnering Current Partnerships Contact Driving Directions Privacy Policy Cookie Policy © 2020 Ultragenyx Pharmaceutical Website Design : Hane Chow, Inc. Privacy Policy Cookie Policy...
ultragenyx.com Whois
"domain_name": "ULTRAGENYX.COM",
"registrar": "GoDaddy.com, LLC",
"whois_server": "whois.godaddy.com",
"referral_url": null,
"updated_date": [
"2017-12-07 18:56:53",
"2017-12-07 18:56:52"
],
"creation_date": "2010-03-12 18:52:56",
"expiration_date": "2026-07-27 11:59:59",
"name_servers": [
"NS0.DNSMADEEASY.COM",
"NS1.DNSMADEEASY.COM",
"NS2.DNSMADEEASY.COM",
"NS3.DNSMADEEASY.COM",
"NS4.DNSMADEEASY.COM"
],
"status": [
"clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited",
"clientRenewProhibited https://icann.org/epp#clientRenewProhibited",
"clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited",
"clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited",
"clientUpdateProhibited http://www.icann.org/epp#clientUpdateProhibited",
"clientRenewProhibited http://www.icann.org/epp#clientRenewProhibited",
"clientDeleteProhibited http://www.icann.org/epp#clientDeleteProhibited"
],
"emails": [
"abuse@godaddy.com",
"ULTRAGENYX.COM@domainsbyproxy.com"
],
"dnssec": "unsigned",
"name": "Registration Private",
"org": "Domains By Proxy, LLC",
"address": [
"DomainsByProxy.com",
"14455 N. Hayden Road"
],
"city": "Scottsdale",
"state": "Arizona",
"zipcode": "85260",
"country": "US"